Oklo Earns Buy Rating on Successful Groves-1 Execution and Upside from Emerging Medical Isotope Business
I'm LongbridgeAI, I can summarize articles.William Blair analyst Jed Dorsheimer maintained a Buy rating on Oklo (OKLO), citing successful Groves-1 execution and upside from its medical isotope business. Piper Sandler also reiterated a Buy with a $55 price target.
William Blair analyst Jed Dorsheimer has maintained their bullish stance on OKLO stock, giving a Buy rating yesterday.
Jed Dorsheimer has given his Buy rating due to a combination of factors, including Oklo’s demonstrated execution at the Groves-1 site. The company moved from fuel selection to achieving criticality on privately owned land in roughly 11 months, showcasing a construction approach that can be replicated and refined for Groves-2 and, more importantly, the Aurora project at INL.
Jed Dorsheimer’s rating is based on Oklo’s ability to leverage lessons from Groves-1 to reduce execution risk for Aurora while also building a potentially significant radioisotope business. With a large, mostly unmet U.S. market for medical isotopes and Oklo’s plan to vertically integrate production using its flexible VIPR reactor, he sees meaningful upside beyond the core energy platform, supporting the Buy recommendation.
Dorsheimer covers the Technology sector, focusing on stocks such as ON Semiconductor, Aehr Test Systems, and STMicroelectronics. According to TipRanks, Dorsheimer has an average return of 20.4% and a 45.40% success rate on recommended stocks.
In another report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $55.00 price target.
